Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

Diabetes

Volumn 50, Issue 6, 2001, Pages 1330-1335

  Van Heek, Margaret ^a   Austin, Theodore M ^a   Farley, Constance ^a   Cook, John A ^a   Tetzloff, Glen G ^a   Davis, Harry R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; EZETIMIBE; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DYSLIPIDEMIA; HAMSTER; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

EID: 0034991315     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.6.1330     Document Type: Article

References (22)

1. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
2. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4-hydroxyphenyl)-2-azetidinone (SCH58235): A designed, potent, orally active inhibitor of cholesterol absorption
3. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
4. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH58235): Pooled analysis of two phase II studies
5. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators
8. LIPID: The Long-Term Intervention with Pravastatin in Ischaemic Disease: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Management of dyslipidemia in adults with diabetes (Position Statement)
10. The cholesterol absorption inhibitor ezetimibe (SCH58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis
11. The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors
12. Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids
13. Theoretical considerations of what regulates low-density lipoprotein and high-density lipoprotein cholesterol
14. Design criteria for studies examining individual fatty acid effect on cardiovascular disease factors: Human and animal studies
15. Dietary fat saturation effects on low-density-lipoprotein concentrations and metabolism in various animal models
16. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations
17. A simple method for isolation and purification of total lipids from animal tissues
18. The effect of acyl CoA: Cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine
19. Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men
20. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster
21. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH58235 and simvastatin
22. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol